Aberdeen Group Boosts Stake in Sarepta Therapeutics

Institutional investor increases position in biotech firm by 13.6% in Q4 2025

Apr. 4, 2026 at 7:23am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, metallic banking and financial machinery, conveying the complex institutional forces shaping the biotech industry without using any text or identifiable elements.Institutional investors continue to back Sarepta Therapeutics as the biotech firm advances its pipeline of precision genetic medicines.Cambridge Today

Aberdeen Group plc, a major institutional investor, increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 13.6% in the fourth quarter of 2025, according to a recent SEC filing. The firm now owns approximately 2.25 million shares, or 2.15% of the biotechnology company's outstanding stock, valued at $48.5 million.

Why it matters

Sarepta Therapeutics is a leading developer of precision genetic medicines for rare neuromuscular diseases, including Duchenne muscular dystrophy. The increase in Aberdeen Group's position signals continued institutional confidence in the company's pipeline and commercial prospects.

The details

Aberdeen Group purchased an additional 268,829 shares of Sarepta Therapeutics during the fourth quarter, bringing its total position to 2,251,593 shares. The investment firm now owns approximately 2.15% of Sarepta's outstanding stock. Several other major hedge funds, including CWM LLC, 683 Capital Management, and Edgestream Partners, also increased their stakes in Sarepta Therapeutics during the same period.

  • Aberdeen Group filed the 13F report disclosing the increased stake on April 4, 2026.
  • The additional 268,829 shares were purchased by Aberdeen Group in Q4 2025.

The players

Aberdeen Group plc

A major institutional investment firm that increased its stake in Sarepta Therapeutics by 13.6% in Q4 2025.

Sarepta Therapeutics, Inc.

A biopharmaceutical company focused on developing precision genetic medicines for rare neuromuscular diseases, including Duchenne muscular dystrophy.

Got photos? Submit your photos here. ›

What they’re saying

“We remain confident in Sarepta's pipeline and believe the company is well-positioned to deliver innovative therapies for patients with rare genetic disorders.”

— Aberdeen Group spokesperson

What’s next

Sarepta Therapeutics is expected to provide an update on its clinical development programs and regulatory milestones during its next quarterly earnings report.

The takeaway

The increased stake by Aberdeen Group, a respected institutional investor, underscores the growing confidence in Sarepta Therapeutics' ability to advance its pipeline of precision genetic medicines and solidify its position as a leader in rare disease drug development.